Michael E. DeBakey Professor in Pharmacology Baylor College of Medicine Houston, Texas
One common feature for immune checkpoint blockades (ICBs) and cell therapies is that they kill cancer cells through granule exocytosis and death ligands to activate programmed cell death. However, cancer cells that are insensitive to these programmed death mechanisms will evade killing mediated by the antitumor immunity. We developed a novel PROTAC that can synergize with anti-PD1 to trigger immunogenic cell death and significantly inhibit tumor growth in an immunotherapy insensitive B16F10 mouse melanoma model.
Learning Objectives:
Upon completion, participants will be able to understand the basics of RIPK1 biology in the immunotherapy context.
Upon completion, participants will be able to understand the pros and cons of PROTACs.
Upon completion, participants will be able to understand immunogenic cell death.
